Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rodolfo Oviedo

Surgery Nacogdoches, TX Medical Doctor

NPI 1376795955 CMS profile 198700

4848 Ne Stallings Dr Ste 201, Nacogdoches, TX 75965

Open in the dashboard

General payments

$148,987

209 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rodolfo Oviedo of Nacogdoches, TX is reported in the CMS Open Payments database as having received $148,987 across 209 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $551 5
2024 General $13,763 25
2023 General $40,068 52
2022 General $34,181 50
2021 General $37,355 40
2020 General $13,119 14
2019 General $9,952 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rodolfo Oviedo
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Rodolfo Oviedo were reported at $551. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Rodolfo Oviedo Surgery median Middle half National median
2019 $9,952 $253 $82–$1,521 $163
2020 $13,119 $131 $40–$706 $114
2021 $37,355 $168 $50–$904 $132
2022 $34,181 $224 $76–$1,218 $149
2023 $40,068 $253 $82–$1,255 $160
2024 $13,763 $279 $90–$1,381 $164
2025 $551 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. TELA Bio, Inc. $72,771 96 payments
  2. Intuitive Surgical, Inc. $40,202 36 payments
  3. W. L. Gore & Associates, Inc. $25,450 31 payments
  4. Medical Device Business Services, Inc. $6,682 4 payments
  5. Boston Scientific Corporation $2,322 15 payments
  6. Endogastric Solutions, Inc $523 5 payments
  7. Nutech Spine, Inc. $194 1 payment
  8. Davol Inc. $145 2 payments
  9. Baxter Healthcare $139 1 payment
  10. CONMED Corporation $111 2 payments
  11. Other $447 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $79,505 31 payments
  2. Education $36,000 9 payments
  3. Honoraria $15,620 5 payments
  4. Food and Beverage $9,366 131 payments
  5. Travel and Lodging $6,395 31 payments
  6. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,000 1 payment
  7. Gift $101 1 payment
Products named General payments · program years 2019–2025
  1. OviTex Reinforced Bioscaffold With Permanent Polymer (OviTex) $61,504 88 payments
  2. Da Vinci Surgical System $38,202 35 payments
  3. OviTex 2S $11,267 8 payments
  4. GORE SYNECOR Biomaterial $10,873 7 payments
  5. Echelon Flex $6,583 2 payments
  6. ECHELON ENDOPATH $6,583 2 payments
  7. Product in Development $6,215 2 payments
  8. SYNECOR Biomaterial $3,982 14 payments
  9. DA VINCI SP $2,000 1 payment
  10. SEAMGUARD Bioabsorbable Staple Line Reinforcement $1,947 3 payments
  11. Other $5,827 44 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

334

Median for General Surgery: 59

Drug cost

$1,975

Median for General Surgery: $393

Branded share of claims

24.9%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Omeprazole Generic 71 $522
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 19 $330
Scopolamine Generic 15 $235
Ondansetron Hcl Generic 46 $188
Sucralfate Generic 14 $164
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 51 $160
Peg-3350 And Electrolytes Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 13 $154
Methocarbamol Generic 39 $107
Gabapentin Generic 24 $38
Tramadol Hcl Generic 18 $35

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 77 billing codes

Paid by Medicare

$83,693

Medicare's payments for the services billed

Medicare patients

121

Average age 71

Services billed

468

62 women, 59 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Diabetes 40%
COPD 40%
Ischemic heart disease 31%
Heart failure 30%
Chronic kidney disease 29%
Atrial fibrillation 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

209 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record